Genus PLC (GNS) - Net Assets
Based on the latest financial reports, Genus PLC (GNS) has net assets worth GBX476.00 Million GBX (≈ $57.92K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX899.00 Million ≈ $109.38K USD) and total liabilities (GBX423.00 Million ≈ $51.47K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Genus PLC liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX476.00 Million |
| % of Total Assets | 52.95% |
| Annual Growth Rate | 10.82% |
| 5-Year Change | -4.15% |
| 10-Year Change | 29.31% |
| Growth Volatility | 69.56 |
Genus PLC - Net Assets Trend (1996–2025)
This chart illustrates how Genus PLC's net assets have evolved over time, based on quarterly financial data. Also explore GNS total asset value for the complete picture of this company's asset base.
Annual Net Assets for Genus PLC (1996–2025)
The table below shows the annual net assets of Genus PLC from 1996 to 2025. For live valuation and market cap data, see Genus PLC (GNS) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | GBX476.00 Million ≈ $57.92K |
-12.48% |
| 2024-06-30 | GBX543.90 Million ≈ $66.18K |
-4.11% |
| 2023-06-30 | GBX567.20 Million ≈ $69.01K |
-0.86% |
| 2022-06-30 | GBX572.10 Million ≈ $69.61K |
+15.20% |
| 2021-06-30 | GBX496.60 Million ≈ $60.42K |
+0.42% |
| 2020-06-30 | GBX494.50 Million ≈ $60.17K |
+1.52% |
| 2019-06-30 | GBX487.10 Million ≈ $59.27K |
+16.23% |
| 2018-06-30 | GBX419.10 Million ≈ $50.99K |
+4.23% |
| 2017-06-30 | GBX402.10 Million ≈ $48.92K |
+9.24% |
| 2016-06-30 | GBX368.10 Million ≈ $44.79K |
+20.65% |
| 2015-06-30 | GBX305.10 Million ≈ $37.12K |
+6.94% |
| 2014-06-30 | GBX285.30 Million ≈ $34.71K |
-5.06% |
| 2013-06-30 | GBX300.50 Million ≈ $36.56K |
+9.03% |
| 2012-06-30 | GBX275.60 Million ≈ $33.53K |
+1.36% |
| 2011-06-30 | GBX271.90 Million ≈ $33.08K |
+7.98% |
| 2010-06-30 | GBX251.80 Million ≈ $30.64K |
+23.07% |
| 2009-06-30 | GBX204.60 Million ≈ $24.89K |
+10.53% |
| 2008-06-30 | GBX185.10 Million ≈ $22.52K |
+22.66% |
| 2007-06-30 | GBX150.90 Million ≈ $18.36K |
+4.79% |
| 2006-06-30 | GBX144.00 Million ≈ $17.52K |
+41.97% |
| 2006-03-31 | GBX101.43 Million ≈ $12.34K |
+97.76% |
| 2005-03-31 | GBX51.29 Million ≈ $6.24K |
+5.31% |
| 2004-03-31 | GBX48.70 Million ≈ $5.93K |
-1.45% |
| 2003-12-31 | GBX49.42 Million ≈ $6.01K |
+3.66% |
| 2003-03-31 | GBX47.68 Million ≈ $5.80K |
+245.58% |
| 2002-12-31 | GBX13.80 Million ≈ $1.68K |
-71.57% |
| 2002-03-31 | GBX48.53 Million ≈ $5.90K |
+300.12% |
| 2001-12-31 | GBX12.13 Million ≈ $1.48K |
-74.93% |
| 2001-03-31 | GBX48.37 Million ≈ $5.89K |
+10.68% |
| 2000-03-31 | GBX43.70 Million ≈ $5.32K |
+37.41% |
| 1999-03-31 | GBX31.80 Million ≈ $3.87K |
+16.01% |
| 1998-03-31 | GBX27.42 Million ≈ $3.34K |
-0.12% |
| 1997-03-31 | GBX27.45 Million ≈ $3.34K |
+16.35% |
| 1996-03-31 | GBX23.59 Million ≈ $2.87K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Genus PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 54132.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | GBX321.60 Million | 67.62% |
| Common Stock | GBX6.60 Million | 1.39% |
| Other Comprehensive Income | GBX-31.10 Million | -6.54% |
| Other Components | GBX178.50 Million | 37.53% |
| Total Equity | GBX475.60 Million | 100.00% |
Genus PLC Competitors by Market Cap
The table below lists competitors of Genus PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Blender Financial Technologies Ltd
TA:BLND
|
$19.05 Million |
|
Epsium Enterprise Limited Ordinary Shares
NASDAQ:EPSM
|
$19.06 Million |
|
CNFinance Holdings Ltd
NYSE:CNF
|
$19.07 Million |
|
Nexen Tire Prf 1
KO:002355
|
$19.07 Million |
|
NexgenRX Inc.
V:NXG
|
$19.03 Million |
|
Austin Gold Corp
NYSE MKT:AUST
|
$19.03 Million |
|
Medifron DBT Co. Ltd
KQ:065650
|
$19.03 Million |
|
Ozaurum Resources Ltd
AU:OZM
|
$19.03 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genus PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 548,200,000 to 475,600,000, a change of -72,600,000 (-13.2%).
- Net income of 19,300,000 contributed positively to equity growth.
- Dividend payments of 21,100,000 reduced retained earnings.
- Other comprehensive income decreased equity by 42,500,000.
- Other factors decreased equity by 28,300,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX19.30 Million | +4.06% |
| Dividends Paid | GBX21.10 Million | -4.44% |
| Other Comprehensive Income | GBX-42.50 Million | -8.94% |
| Other Changes | GBX-28.30 Million | -5.95% |
| Total Change | GBX- | -13.24% |
Book Value vs Market Value Analysis
This analysis compares Genus PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 331.10x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 2295.29x to 331.10x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-03-31 | GBX1.03 | GBX2356.00 | x |
| 1997-03-31 | GBX1.19 | GBX2356.00 | x |
| 1998-03-31 | GBX0.85 | GBX2356.00 | x |
| 1999-03-31 | GBX0.98 | GBX2356.00 | x |
| 2000-03-31 | GBX1.35 | GBX2356.00 | x |
| 2001-03-31 | GBX1.46 | GBX2356.00 | x |
| 2002-03-31 | GBX1.47 | GBX2356.00 | x |
| 2003-03-31 | GBX1.39 | GBX2356.00 | x |
| 2004-03-31 | GBX1.41 | GBX2356.00 | x |
| 2005-03-31 | GBX1.40 | GBX2356.00 | x |
| 2006-06-30 | GBX3.10 | GBX2356.00 | x |
| 2007-06-30 | GBX2.67 | GBX2356.00 | x |
| 2008-06-30 | GBX3.16 | GBX2356.00 | x |
| 2009-06-30 | GBX3.42 | GBX2356.00 | x |
| 2010-06-30 | GBX4.18 | GBX2356.00 | x |
| 2011-06-30 | GBX4.48 | GBX2356.00 | x |
| 2012-06-30 | GBX4.52 | GBX2356.00 | x |
| 2013-06-30 | GBX4.92 | GBX2356.00 | x |
| 2014-06-30 | GBX4.69 | GBX2356.00 | x |
| 2015-06-30 | GBX5.06 | GBX2356.00 | x |
| 2016-06-30 | GBX6.10 | GBX2356.00 | x |
| 2017-06-30 | GBX6.46 | GBX2356.00 | x |
| 2018-06-30 | GBX6.71 | GBX2356.00 | x |
| 2019-06-30 | GBX7.48 | GBX2356.00 | x |
| 2020-06-30 | GBX7.57 | GBX2356.00 | x |
| 2021-06-30 | GBX7.59 | GBX2356.00 | x |
| 2022-06-30 | GBX8.80 | GBX2356.00 | x |
| 2023-06-30 | GBX8.63 | GBX2356.00 | x |
| 2024-06-30 | GBX8.28 | GBX2356.00 | x |
| 2025-06-30 | GBX7.12 | GBX2356.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genus PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.06%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.87%
- • Asset Turnover: 0.75x
- • Equity Multiplier: 1.89x
- Recent ROE (4.06%) is below the historical average (8.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | 1.83% | 0.90% | 1.49x | 1.37x | GBX-1.93 Million |
| 1997 | 16.56% | 9.75% | 1.27x | 1.34x | GBX1.80 Million |
| 1998 | 11.52% | 6.64% | 1.23x | 1.41x | GBX417.40K |
| 1999 | 12.43% | 6.90% | 1.21x | 1.49x | GBX772.00K |
| 2000 | 7.86% | 2.57% | 1.29x | 2.37x | GBX-931.80K |
| 2001 | 3.11% | 0.92% | 1.57x | 2.16x | GBX-3.32 Million |
| 2002 | 1.17% | 0.35% | 1.69x | 1.96x | GBX-4.27 Million |
| 2003 | 5.80% | 1.59% | 1.70x | 2.14x | GBX-1.99 Million |
| 2004 | 10.83% | 2.87% | 1.93x | 1.95x | GBX402.50K |
| 2005 | 10.86% | 4.89% | 1.09x | 2.04x | GBX440.00K |
| 2006 | 5.42% | 3.88% | 0.44x | 3.17x | GBX-6.60 Million |
| 2007 | 9.68% | 6.24% | 0.54x | 2.88x | GBX-490.00K |
| 2008 | 9.56% | 7.16% | 0.57x | 2.36x | GBX-810.00K |
| 2009 | 8.75% | 6.38% | 0.56x | 2.43x | GBX-2.56 Million |
| 2010 | 10.93% | 9.64% | 0.53x | 2.16x | GBX2.35 Million |
| 2011 | 10.75% | 9.42% | 0.57x | 1.99x | GBX2.04 Million |
| 2012 | 14.35% | 11.56% | 0.58x | 2.14x | GBX11.98 Million |
| 2013 | 9.00% | 7.82% | 0.57x | 2.03x | GBX-3.01 Million |
| 2014 | 10.15% | 7.76% | 0.64x | 2.05x | GBX430.00K |
| 2015 | 12.84% | 10.01% | 0.62x | 2.07x | GBX8.82 Million |
| 2016 | 13.16% | 12.70% | 0.53x | 1.97x | GBX11.85 Million |
| 2017 | 8.21% | 7.14% | 0.58x | 2.00x | GBX-7.13 Million |
| 2018 | 10.25% | 9.08% | 0.60x | 1.89x | GBX1.04 Million |
| 2019 | 1.60% | 1.60% | 0.61x | 1.65x | GBX-41.04 Million |
| 2020 | 7.12% | 6.40% | 0.64x | 1.73x | GBX-14.25 Million |
| 2021 | 9.50% | 8.24% | 0.67x | 1.71x | GBX-2.51 Million |
| 2022 | 7.07% | 6.89% | 0.58x | 1.76x | GBX-16.95 Million |
| 2023 | 5.85% | 4.83% | 0.68x | 1.77x | GBX-23.64 Million |
| 2024 | 1.44% | 1.18% | 0.65x | 1.88x | GBX-46.92 Million |
| 2025 | 4.06% | 2.87% | 0.75x | 1.89x | GBX-28.26 Million |
Industry Comparison
This section compares Genus PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $8,864,748
- Average return on equity (ROE) among peers: -251.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genus PLC (GNS) | GBX476.00 Million | 1.83% | 0.89x | $19.04 Million |
| 4BASEBIO UK SOCIETAS (4BB) | $7.12 Million | -72.33% | 0.64x | $951.45K |
| Aptamer Group PLC (APTA) | $245.81K | -274.50% | 4.65x | $205.09K |
| Arecor Therapeutics PLC (AREC) | $5.35 Million | -191.36% | 0.63x | $303.20K |
| Avacta Group PLC (AVCT) | $29.89 Million | -21.30% | 0.06x | $3.99 Million |
| BSF Enterprise Plc (BSFA) | $3.58 Million | -25.96% | 0.13x | $27.33K |
| Bioventix (BVXP) | $11.01 Million | 51.43% | 0.08x | $1.10 Million |
| Cizzle Biotechnology Holdings PLC (CIZ) | $32.00K | -956.25% | 1.81x | $127.81K |
| Amur Minerals Corporation (CRTX) | $20.48 Million | -8.91% | 0.04x | $80.26K |
| Fusion Antibodies PLC (FAB) | $50.13K | -935.06% | 5.06x | $193.60K |
| Faron Pharmaceuticals Oy (FARN) | $10.88 Million | -85.40% | 0.59x | $575.13K |
About Genus PLC
Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It offers dairy and beef bull semen and embryos under the Genus and Bovec brands; breeding pork and semen, as well as techni… Read more